Chlamydia Control: A Comparative Review from the USA and UK

  • Nicola LowEmail author
  • William M. Geisler
  • Judith M. Stephenson
  • Edward W. HookIII


Chlamydia trachomatis infection (chlamydia) is the most common notifiable bacterial sexually transmitted infection (STI) worldwide. In the United States of America (USA) in 2009, 1,244,180 cases of chlamydia were reported to the Centers for Disease Control and Prevention (CDC), the largest number of cases ever reported to CDC for any notifiable disease [1]. It has been estimated, from population prevalence surveys, that approximately 2 % of sexually active adults aged 18–44 years old in the UK [2] and 2.2 % (CI, 1.8–2.8 %) of the US population aged 14–39 years [3] are infected with chlamydia. This level of prevalence in the USA translates into an estimated 2,291,000 (95 % confidence interval, CI, 1,857,000–2,838,000) chlamydia infections each year [3]. Globally, the World Health Organization (WHO) estimates that there are about 92 million new cases of chlamydia each year [4].


Ectopic Pregnancy Pelvic Inflammatory Disease Chlamydia Infection Partner Notification Chlamydia Screening 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Centers for Disease Control and Prevention. Sexually transmitted disease surveillance 2009. Atlanta: U.S. Department of Health and Human Services; 2010.Google Scholar
  2. 2.
    Fenton KA, Korovessis C, Johnson AM, et al. Sexual behaviour in Britain: reported sexually transmitted infections and prevalent genital Chlamydia trachomatis infection. Lancet. 2001;358:1851–4.PubMedCrossRefGoogle Scholar
  3. 3.
    Datta SD, Sternberg M, Johnson RE, et al. Gonorrhea and chlamydia in the United States among persons 14 to 39 years of age, 1999 to 2002. Ann Intern Med. 2007;147(2):89–96.PubMedGoogle Scholar
  4. 4.
    World Health Organization. Global prevalence and incidence of selected curable sexually transmitted infections. Overview and estimates. Geneva: World Health Organisation; 2001.Google Scholar
  5. 5.
    Cates Jr W, Rolfs Jr RT, Aral SO. Sexually transmitted diseases, pelvic inflammatory disease, and infertility: an epidemiologic update. Epidemiol Rev. 1990;12:199–220.PubMedGoogle Scholar
  6. 6.
    Mardh PA, Ripa T, Svensson L, Westrom L. Chlamydia trachomatis infection in patients with acute salpingitis. N Engl J Med. 1977;296(24):1377–9.PubMedCrossRefGoogle Scholar
  7. 7.
    Westrom L. Effect of acute pelvic inflammatory disease on fertility. Am J Obstet Gynecol. 1975;121(5):707–13.PubMedGoogle Scholar
  8. 8.
    Svensson L, Mardh PA, Westrom L. Infertility after acute salpingitis with special reference to Chlamydia trachomatis. Fertil Steril. 1983;40(3):322–9.PubMedGoogle Scholar
  9. 9.
    Washington AE, Katz P. Ectopic pregnancy in the United States: economic consequences and payment source trends. Obstet Gynecol. 1993;81(2):287–92.PubMedGoogle Scholar
  10. 10.
    Washington AE, Arno PS, Brooks MA. The economic cost of pelvic inflammatory disease. JAMA. 1986;255(13):1735–8.PubMedCrossRefGoogle Scholar
  11. 11.
    Washington AE, Cates WJ, Wasserheit JN. Preventing pelvic inflammatory disease. JAMA. 1991;266(18):2574–80.PubMedCrossRefGoogle Scholar
  12. 12.
    Low N. Screening programmes for chlamydial infection: when will we ever learn? BMJ. 2007;334(7596):725–8.PubMedCrossRefGoogle Scholar
  13. 13.
    Berridge V. AIDS in the UK: the making of Policy, 1981–1994. Oxford: Oxford University Press; 1996.Google Scholar
  14. 14.
    Ripa T. Epidemiologic control of genital Chlamydia trachomatis infections. Scand J Infect Dis Suppl. 1990;69:157–67.PubMedGoogle Scholar
  15. 15.
    Herrmann BF, Johansson AB, Mardh PA. A retrospective study of efforts to diagnose infections by Chlamydia trachomatis in a Swedish county. Sex Transm Dis. 1991;18(4):233–7.PubMedCrossRefGoogle Scholar
  16. 16.
    Addiss D, Vaughin ML, Ludka D, Pfister J, Davis JP. Decreased prevalence of Chlamydia trachomatis infection associated with a selective screening program in family planning clinics in Wisconsin. Sex Transm Dis. 1993;20:28–34.PubMedCrossRefGoogle Scholar
  17. 17.
    Nicoll A, Hughes G, Donnelly M, et al. Assessing the impact of national anti-HIV sexual health campaigns: trends in the transmission of HIV and other sexually transmitted infections in England. Sex Transm Infect. 2001;77(4):242–7.PubMedCrossRefGoogle Scholar
  18. 18.
    Coutinho RA, Rijsdijk AJ, van den Hoek JA, Leentvaar-Kuijpers A. Decreasing incidence of PID in Amsterdam. Genitourin Med. 1992;68(6):353–5.PubMedGoogle Scholar
  19. 19.
    U.S. Preventive Services Task Force. Screening for chlamydial infection: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2007;147:128–34.Google Scholar
  20. 20.
    Centers for Disease Control and Prevention. Sexually transmitted diseases treatment guidelines, 2010. MMWR Recomm Rep. 2010; 59(RR-12); 44–5.Google Scholar
  21. 21.
    Royal Australian College of General Practitioners. Guidelines for preventive activities in general practice. Melbourne: RACGP; 2007.Google Scholar
  22. 22.
    Department of Health. National Chlamydia Screening Programme (NCSP) in England: programme overview; core requirements; data collection. 2nd ed. London: Department of Health; 2004. Accessed 6 Sep 2012.Google Scholar
  23. 23.
    Low N, Bender N, Nartey L, Shang A, Stephenson JM. Effectiveness of chlamydia screening: systematic review. Int J Epidemiol. 2009;38(2):435–48.PubMedCrossRefGoogle Scholar
  24. 24.
    Gottlieb SL, Berman SM, Low N. Screening and treatment to prevent sequelae in women with Chlamydia trachomatis genital infection: how much do we know? J Infect Dis. 2010;201 Suppl 2:S156–67.PubMedCrossRefGoogle Scholar
  25. 25.
    Hay PE, Pittrof RU. Has the effectiveness of a single chlamydia test in preventing pelvic inflammatory disease over 12 months been overestimated? Womens Health (Lond Engl). 2010;6(5):627–30.CrossRefGoogle Scholar
  26. 26.
    Stamm WE. Chlamydia trachomatis infections of the adult. In: Holmes KK, Sparling PF, Stamm WE, Piot P, Wasserheit JN, Corey L, et al., editors. Sexually transmitted diseases. 4th ed. New York: McGraw Hill Medical; 2008. p. 575–93.Google Scholar
  27. 27.
    Geisler WM. Duration of untreated, uncomplicated Chlamydia trachomatis genital infection and factors associated with chlamydia resolution: a review of human studies. J Infect Dis. 2010;201(S2):104–13.CrossRefGoogle Scholar
  28. 28.
    Batteiger BE, Xu F, Johnson RE, Rekart ML. Protective immunity to Chlamydia trachomatis genital infection: evidence from human studies. J Infect Dis. 2010;201 Suppl 2:S178–89.PubMedCrossRefGoogle Scholar
  29. 29.
    Paavonen J, Westrom L, Eschenbach D. Chapter 56. Pelvic inflammatory disease. In: Holmes KK, Sparling PF, Stamm WE, Piot P, Wasserheit JN, Corey L, et al., editors. Sexually transmitted diseases. 4th ed. New York: McGraw Hill Medical; 2008. p. 1017–50.Google Scholar
  30. 30.
    Haggerty CL, Gottlieb SL, Taylor BD, Low N, Xu F, Ness RB. Risk of sequelae after Chlamydia trachomatis genital infection in women. J Infect Dis. 2010;201 Suppl 2:S134–55.PubMedCrossRefGoogle Scholar
  31. 31.
    van Valkengoed IG, Morre SA, van den Brule AJ, Meijer CJ, Bouter LM, Boeke AJ. Overestimation of complication rates in evaluations of Chlamydia trachomatis screening programmes—implications for cost-effectiveness analyses. Int J Epidemiol. 2004;33(2):416–25.PubMedCrossRefGoogle Scholar
  32. 32.
    Geisler WM, Wang C, Morrison SG, Black CM, Bandea CI, Hook III EW. The natural history of untreated Chlamydia trachomatis infection in the interval between screening and returning for treatment. Sex Transm Dis. 2008;35(2):119–23.PubMedCrossRefGoogle Scholar
  33. 33.
    Hook III EW, Spitters C, Reichart CA, Neumann TM, Quinn TC. Use of cell culture and a rapid diagnostic assay for Chlamydia trachomatis screening. JAMA. 1994;272(11):867–70.PubMedCrossRefGoogle Scholar
  34. 34.
    Wein P, Kloss M, Garland SM. Postabortal pelvic sepsis in association with Chlamydia trachomatis. Aust N Z J Obstet Gynaecol. 1990;30(4):347–50.PubMedCrossRefGoogle Scholar
  35. 35.
    Qvigstad E, Skaug K, Jerve F. Pelvic inflammatory disease associated with Chlamydia trachomatis infection after therapeutic abortion. A prospective study. Br J Vener Dis. 1983;59(3):189–92.PubMedGoogle Scholar
  36. 36.
    Rice PA, Schachter J. Pathogenesis of pelvic inflammatory disease. What are the questions? JAMA. 1991;266(18):2587–93.PubMedCrossRefGoogle Scholar
  37. 37.
    Westrom L, Joesoef R, Reynolds G, Hagdu A, Thompson SE. Pelvic inflammatory disease and fertility. A cohort study of 1, 844 women with laparoscopically verified disease and 657 control women with normal laparoscopic results. Sex Transm Dis. 1992;19(4):185–92.PubMedCrossRefGoogle Scholar
  38. 38.
    Westrom L. Pelvic inflammatory disease. JAMA. 1991;266(18):2612.PubMedCrossRefGoogle Scholar
  39. 39.
    Wasserheit JN, Aral SO. The dynamic topology of sexually transmitted disease epidemics: implications for prevention strategies. J Infect Dis. 1996;174 Suppl 2:S201–13.PubMedCrossRefGoogle Scholar
  40. 40.
    Garnett GP. The geographical and temporal evolution of sexually transmitted disease epidemics. Sex Transm Infect. 2002;78 Suppl 1:i14–9.PubMedCrossRefGoogle Scholar
  41. 41.
    Miller WC, Ford CA, Morris M, et al. Prevalence of chlamydial and gonococcal infections among young adults in the United States. JAMA. 2004;291(18):2229–36.PubMedCrossRefGoogle Scholar
  42. 42.
    Hosenfeld CB, Workowski KA, Berman S, et al. Repeat infection with Chlamydia and gonorrhea among females: a systematic review of the literature. Sex Transm Dis. 2009;36(8):478–89.PubMedCrossRefGoogle Scholar
  43. 43.
    Gordon FB, Quan AL. Isolation of the trachoma agent in cell culture. Proc Soc Exp Biol Med. 1965;118:354–9.PubMedGoogle Scholar
  44. 44.
    Johnson RE, Newhall WJ, Papp JR, et al. Screening tests to detect Chlamydia trachomatis and Neisseria gonorrhoeae infections—2002. MMWR Recomm Rep. 2002;51(RR-15):1–38.PubMedGoogle Scholar
  45. 45.
    Health Protection Agency. STI annual data tables (Topics, Sexually transmitted infections, disease statistics and surveillance). Accessed 6 Sep 2012.
  46. 46.
    Miller WC. Epidemiology of chlamydial infection: are we losing ground? Sex Transm Infect. 2008;84(2):82–6.PubMedCrossRefGoogle Scholar
  47. 47.
    Low N. Caution: chlamydia surveillance data ahead. Sex Transm Infect. 2008;84(2):80–1.PubMedCrossRefGoogle Scholar
  48. 48.
    Centers for Disease Control and Prevention. Sexually transmitted disease surveillance 2007 supplement, Chlamydia Prevalence Monitoring Project. Atlanta, GA: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention; 2009.Google Scholar
  49. 49.
    Last JM. A dictionary of epidemiology. Oxford: Oxford University Press; 2001.Google Scholar
  50. 50.
    Low N, Sterne JA, Barlow D. Inequalities in rates of gonorrhoea and chlamydia between Black ethnic groups in South East London: cross-sectional study. Sex Transm Infect. 2001;77:15–20.PubMedCrossRefGoogle Scholar
  51. 51.
    Simms I, Talebi A, Riha J, et al. The English National Chlamydia Screening Programme: variations in positivity in 2007/2008. Sex Transm Dis. 2009;36(8):522–7.PubMedCrossRefGoogle Scholar
  52. 52.
    Datta SD, Torrone E, Kruszon-Moran D, et al. Chlamydia trachomatis trends in the United States among persons 14 to 39 years of age, 1999–2008. Sex Transm Dis. 2011;39(2):92–6.Google Scholar
  53. 53.
    Health Protection Agency. National Chlamydia Screening Programme. NCSP: five years. The fifth annual report of the National Chlamydia Screening Programme 2007/8. London: Health Protection Agency; 2008.Google Scholar
  54. 54.
    World Health Organization. ICD-10. International statistical classification of diseases and related health problems. Tenth Revisionth ed. Geneva: World Health Organization; 1992.Google Scholar
  55. 55.
    French CE, Hughes G, Nicholson A, et al. Estimation of the rate of pelvic inflammatory disease diagnoses: trends in England, 2000–2008. Sex Transm Dis. 2011;38(3):158–62.PubMedCrossRefGoogle Scholar
  56. 56.
    Simms I, Warburton F, Westrom L. Diagnosis of pelvic inflammatory disease: time for a rethink. Sex Transm Infect. 2003;79(6):491–4.PubMedCrossRefGoogle Scholar
  57. 57.
    Chen MY, Fairley CK, Donovan B. Discordance between trends in chlamydia notifications and hospital admission rates for chlamydia related diseases in New South Wales, Australia. Sex Transm Infect. 2005;81(4):318–22.PubMedCrossRefGoogle Scholar
  58. 58.
    Chen MY, Pan Y, Britt H, Donovan B. Trends in clinical encounters for pelvic inflammatory disease and epididymitis in a national sample of Australian general practices. Int J STD AIDS. 2006;17(6):384–6.PubMedCrossRefGoogle Scholar
  59. 59.
    Westrom L. Decrease in incidence of women treated in hospital for acute salpingitis in Sweden. Genitourin Med. 1988;64(1):59–63.PubMedGoogle Scholar
  60. 60.
    Bjartling C. Osser S, Persson K. The frequency of salping it is and ectopic pregnancy as epidermiological markers of Chlamydia trachomatis Acta Obstct Gynew/Scand 2000;79(2):123–8.Google Scholar
  61. 61.
    Centers for Disease Control and Prevention. Sexually transmitted disease surveillance 2008. Atlanta: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention; 2009.Google Scholar
  62. 62.
    Eschenbach DA, Buchanan TM, Pollock HM, et al. Polymicrobial etiology of acute pelvic inflammatory disease. N Engl J Med. 1975;293(4):166–71.PubMedCrossRefGoogle Scholar
  63. 63.
    Morgan J, Colonne C, Bell A. Trends of chlamydia infection and related complications in New Zealand, 1998–2008. Sex Health. 2011;8:412–8.PubMedCrossRefGoogle Scholar
  64. 64.
    Bender N, Herrmann B, Andersen B, et al. Chlamydia infection, pelvic inflammatory disease, ectopic pregnancy and infertility: cross-national study. Sex Transm Infect. 2011;87(7):601–8.PubMedCrossRefGoogle Scholar
  65. 65.
    Parran T. Shadow on the land—syphilis. New York: Reynal & Hitchcock; 1937.Google Scholar
  66. 66.
    Parran T. The eradication of syphilis as a practical public health objective. JAMA. 1931;97(2):73–7.CrossRefGoogle Scholar
  67. 67.
    Low N, Broutet N, Adu-Sarkodie Y, Barton P, Hossain M, Hawkes S. Global control of sexually transmitted infections. Lancet. 2006;368(9551):2001–16.PubMedCrossRefGoogle Scholar
  68. 68.
    Gray JA. New concepts in screening. Br J Gen Pract. 2004;54(501):292–8.PubMedGoogle Scholar
  69. 69.
    Raffle A, Gray M. Screening: evidence and practice. Oxford: Oxford University Press; 2007.CrossRefGoogle Scholar
  70. 70.
    Department of Health. UK Screening Portal. UK National Screening Committee. Programme appraisal criteria. Accessed 6 Sept 2012.
  71. 71.
    National Health Committee. Screening to improve health in New Zealand. Criteria to assess screening programmes. Accessed 20 Oct 2011.
  72. 72.
    Department of Health. CMO’s Expert Advisory Group on Chlamydia trachomatis. London: Department of Health; 1998.Google Scholar
  73. 73.
    Stephenson JM. Screening for genital chlamydial infection. Br Med Bull. 1998;54(4):891–902.PubMedCrossRefGoogle Scholar
  74. 74.
    Low N, McCarthy A, Macleod J, et al. Epidemiological, social, diagnostic and economic evaluation of population screening for genital chlamydial infection. Health Technol Assess. 2007;11(8):1–184.Google Scholar
  75. 75.
    Harris RP, Helfand M, Woolf SH, et al. Current methods of the US Preventive Services Task Force: a review of the process. Am J Prev Med. 2001;20(3 Suppl):21–35.PubMedCrossRefGoogle Scholar
  76. 76.
    Miller WC. Screening for chlamydial infection: are we doing enough? Lancet. 2005;365(9458):456–8.PubMedGoogle Scholar
  77. 77.
    LaMontagne DS, Fenton KA, Randall S, Anderson S, Carter P, on behalf of the National Chlamydia Screening Steering Group. Establishing the National Chlamydia Screening Programme in England: results from the first full year of screening. Sex Transm Infect 2004;80(5):335–41.Google Scholar
  78. 78.
    Centers for Disease Control and Prevention. Sexually transmitted diseases treatment guidelines, 2006. MMWR Recomm Rep. 2006;55(R-11):1–94.Google Scholar
  79. 79.
    Scholes D, Stergachis A, Heidrich FE, Andrilla H, Holmes KK, Stamm WE. Prevention of pelvic inflammatory disease by screening for cervical chlamydial infection. N Engl J Med. 1996;334(21):1362–6.PubMedCrossRefGoogle Scholar
  80. 80.
    Ostergaard L, Andersen B, Moller JK, Olesen F. Home sampling versus conventional swab sampling for screening of chlamydia trachomatis in women: a cluster-randomized 1-year follow-up study. Clin Infect Dis. 2000;31(4):951–7.PubMedCrossRefGoogle Scholar
  81. 81.
    Oakeshott P, Kerry S, Aghaizu A, et al. Randomised controlled trial of screening for Chlamydia trachomatis to prevent pelvic inflammatory disease: the POPI (prevention of pelvic infection) trial. BMJ. 2010;340:c1642.PubMedCrossRefGoogle Scholar
  82. 82.
    van den Broek IVF, Hoebe CJPA, van Bergen JEAM, et al. Evaluation design of a systematic, selective, internet-based, Chlamydia Screening Implementation in the Netherlands, 2008–2010: implications of first results for the analysis. BMC Infect Dis. 2010;10:89.PubMedCrossRefGoogle Scholar
  83. 83.
    van den Broek IVF, van Bergen JEAM, Brouwers EEHG, et al. Effectiveness of yearly, register based screening for chlamydia in the Netherlands: controlled trial with randomised stepped wedge implementation. BJM 2012;345:e4316.Google Scholar
  84. 84.
    Hocking JS, Spark S, Guy R, et al. The australian chlamydia control effectiveness pilot (ACCEPT): first result from a randomised controlled trail of annuals chlamydia screening in general practice. Abstracts of the 4th joint BASHH-ASTDA meeting in Brighton, UK. 27-29 June 2012. Sex translmfert 2012;88(suppl):A35.Google Scholar
  85. 85.
    Herrmann B, Egger M. Genital Chlamydia ­trachomatis infections in Uppsala County, Sweden, 1985–1993: declining rates for how much longer? Sex Transm Dis. 1995;22(4):253–60.PubMedCrossRefGoogle Scholar
  86. 86.
    Kamwendo F, Forslin L, Bodin L, Danielsson D. Decreasing incidences of gonorrhea- and chlamydia-associated pelvic inflammatory disease: a 25-year study from an urban area of central Sweden. Sex Transm Dis. 1996;23(5):384–91.PubMedCrossRefGoogle Scholar
  87. 87.
    LaMontagne DS, Fenton KA, Pimenta JM, et al. Using chlamydia positivity to estimate prevalence: evidence from the Chlamydia Screening Pilot in England. Int J STD AIDS. 2005;16(4):323–7.PubMedCrossRefGoogle Scholar
  88. 88.
    National Chlamydia Screening Programme. England Quarters 1–4 April 2010–March 2011. National Chlamydia Screening Programme. Accessed 20 Oct 2011.
  89. 89.
    Kretzschmar M, Welte R, van Den HA, Postma MJ. Comparative model-based analysis of screening programs for Chlamydia trachomatis infections. Am J Epidemiol. 2001;153(1):90–101.PubMedCrossRefGoogle Scholar
  90. 90.
    Althaus CL, Heijne JCM, Roellin A, Low N. Transmission dynamics of Chlamydia trachomatis affect the impact of screening programmes. Epidemics. 2010;2(3):123–31.PubMedCrossRefGoogle Scholar
  91. 91.
    Regan DG, Wilson DP, Hocking JS. Coverage is the key for effective screening of Chlamydia trachomatis in Australia. J Infect Dis. 2008;198(3):349–58.PubMedCrossRefGoogle Scholar
  92. 92.
    Turner KME, Adams EJ, LaMontagne DS, Emmett L, Baster K, Edmunds WJ. Modelling the effectiveness of chlamydia screening in England. Sex Transm Infect. 2006;82(6):496–502.PubMedCrossRefGoogle Scholar
  93. 93.
    Centers for Disease Control and Prevention. Chlamydia trachomatis infections. Policy guidelines for prevention and control. MMWR Recomm Rep. 1985;34(3):53S–74.Google Scholar
  94. 94.
    Centers for Disease Control and Prevention. Infertility Prevention Project. Accessed 6 Sept 2012.
  95. 95.
    U.S. Preventive Services Task Force. Guide to clinical preventive services: an assessment of the effectiveness of 169 preventive interventions. Baltimore: Williams & Wilkins; 1989.Google Scholar
  96. 96.
    Centers for Disease Control and Prevention. Sexually transmitted diseases treatment guidelines. MMWR Recomm Rep. 1993;42(RR-14):1–102.Google Scholar
  97. 97.
    Centers for Disease Control and Prevention. Recommendations for the prevention and management of Chlamydia trachomatis infections, 1993. MMWR Recomm Rep. 1993;42(RR-12):1–45.Google Scholar
  98. 98.
    Centers for Disease Control and Prevention. Chlamydia trachomatis genital infections—United States, 1995. MMWR Recomm Rep. 1997;46(9):193–8.Google Scholar
  99. 99.
    Mertz KJ, Ransom RL, St Louis ME. Prevalence of genital chlamydial infection in young women entering a national job training program, 1990–1997. Am J Public Health. 2001;91(8):1287–90.PubMedCrossRefGoogle Scholar
  100. 100.
    Centers for Disease Control and Prevention. Division of STD prevention. Tracking the hidden epidemics: trends in STDs in the United States, 2000. Accessed 6 Sept 2012.
  101. 101.
    Centers for Disease Control and Prevention. Guidelines for treatment of sexually transmitted diseases. MMWR Recomm Rep. 1998;47(RR-1):1–118.Google Scholar
  102. 102.
    Centers for Disease Control and Prevention. Chlamydia screening, HEDIS and managed care. Accessed 6 Sept 2012.
  103. 103.
    U.S. Department of Health and Human Services. Midcourse review. Healthy people 2010. Sexually transmitted diseases, 25. Archive accessed 6 Sept 2012.
  104. 104.
    Nelson HD, Helfand M. Screening for chlamydial infection. Am J Prev Med. 2001;20 Suppl 1:95–107.PubMedCrossRefGoogle Scholar
  105. 105.
    Centers for Disease Control and Prevention. Sexually transmitted diseases treatment guidelines 2002. MMWR Recomm Rep. 2002;51(6):1–78.Google Scholar
  106. 106.
    Centers for Disease Control and Prevention. Expedited partner therapy. Dear Colleague Letter. Accessed 6 Sept 2012.
  107. 107.
    Centers for Disease Control and Prevention. Male Chlamydia screening. Dear Colleague Letter. Accessed 6 Sept 2012.
  108. 108.
    Association of Public Health Laboratories, Centers for Disease Control and Prevention. Laboratory diagnostic testing for Chlamydia trachomatis and Neisseria gonorrhoeae: expert consultation meeting summary report. 13–15 Jan 2009. Atlanta, GA. Accessed 6 Sept 2012.
  109. 109.
    Centers for Disease Control and Prevention. Chlamydia screening among sexually active young female enrollees of health plans—United States, 2000–2007. JAMA. 2009;302(6):620–1.Google Scholar
  110. 110.
    Communicable Disease Surveillance Centre. Sexually transmitted diseases quarterly report: genital infection with Chlamydia trachomatis in England and Wales. Commun Dis Rep CDR Wkly. 1995;5(26):122–3.Google Scholar
  111. 111.
    Taylor-Robinson D. Chlamydia trachomatis and sexually transmitted disease. BMJ. 1994;308(6922):150–1.PubMedCrossRefGoogle Scholar
  112. 112.
    Department of Health. First report of the UK National Screening Committee. London: The Stationery Office; 1998.Google Scholar
  113. 113.
    Department of Health. Second report of the National Screening Committee. London: The Stationery Office; 2000.Google Scholar
  114. 114.
    Pimenta JM, Catchpole M, Rogers PA, et al. Opportunistic screening for genital chlamydial infection. I: acceptability of urine testing in primary and secondary healthcare settings. Sex Transm Infect. 2003;79(1):16–21.PubMedCrossRefGoogle Scholar
  115. 115.
    Pimenta JM, Catchpole M, Rogers PA, et al. Opportunistic screening for genital chlamydial infection. II: prevalence among healthcare attenders, outcome, and evaluation of positive cases. Sex Transm Infect. 2003;79(1):22–7.PubMedCrossRefGoogle Scholar
  116. 116.
    Department of Health. National strategy for sexual health and HIV. London: Department of Health; 2001.Google Scholar
  117. 117.
    UK National Screening Committee. Programme director’s report. Period: Autumn 2000–Spring 2002; 2002. Report No.: nsc/annualreport2002/1.7.02.Google Scholar
  118. 118.
    UK National Screening Committee. Note of the meeting held on 8 Dec 2004; 2004.Google Scholar
  119. 119.
    UK National Screening Committee. UK Screening Portal. UK NSC policy database. Policies: Chlamydia (adult), Chlamydia (pregnancy). Accessed 6 Sept 2012.
  120. 120.
    Adams EJ, Turner KM, Edmunds WJ. The cost effectiveness of opportunistic chlamydia screening in England. Sex Transm Infect. 2007;83(4):267–74.PubMedCrossRefGoogle Scholar
  121. 121.
    Health Protection Agency. National Chlamydia Screening Programme. The bigger picture. The National Chlamydia Screening Programme. 2008/09 annual report. London: Health Protection Agency; 2009.Google Scholar
  122. 122.
    National Audit Office. Department of Health. Young people’s sexual health: the National Chlamydia Screening Programme. Report by the Comptroller and Auditor General. HC 963 Session 2008–2009. London: The Stationery Office; 2009.Google Scholar
  123. 123.
    Cancer of the cervix: death by incompetence. Lancet. 1985;2(8451):363–4.Google Scholar
  124. 124.
    UK National Screening Committee. Accessed 6 Sept 2012.
  125. 125.
    Rekart ML, Brunham RC. Epidemiology of chlamydial infection: are we losing ground? Sex Transm Infect. 2008;84(2):87–91.PubMedCrossRefGoogle Scholar
  126. 126.
    Hennekens CH, DeMets D. Statistical association and causation. JAMA. 2011;305(11):1134–5.PubMedCrossRefGoogle Scholar
  127. 127.
    Centers for Disease Control and Prevention. Infertility and prevention of sexually transmitted diseases 2000–2003. Report to Congress. Accessed 6 Sept 2012.
  128. 128.
    Soldan K, Berman SM. Danish health register study: a randomised trial with findings about the implementation of chlamydia screening, but not about its benefits. Sex Transm Infect. 2011;87(2):86–7.PubMedCrossRefGoogle Scholar
  129. 129.
    U.S. Department of Health and Human Services. Healthy people 2020. 2011 September. Accessed 6 Sept 2012.
  130. 130.
    Centers for Disease Control and Prevention. Special focus: surveillance for sexually transmitted diseases. MMWR Recomm Rep. 1993;42(SS-3):1–39.Google Scholar
  131. 131.
    Peterman TA, Gottlieb SL, Berman SM. Commentary: Chlamydia trachomatis screening: what are we trying to do? Int J Epidemiol. 2009;38(2):449–51.PubMedCrossRefGoogle Scholar
  132. 132.
    Tao G, Walsh CM, Anderson LA, Irwin KL. Understanding sexual activity defined in the HEDIS measure of screening young women for Chlamydia trachomatis. Jt Comm J Qual Improv. 2002;28(8):435–40.PubMedGoogle Scholar
  133. 133.
    Heijne JCM, Tao G, Kent CK, Low N. Uptake of regular chlamydia testing by U.S. women: a longitudinal study. Am J Prev Med. 2010;39(3):243–50.PubMedCrossRefGoogle Scholar
  134. 134.
    National Chlamydia Screening Programme. NHS Vital Signs 2010/11. Primary Care Trust (PCT) and Strategic Health Authority (SHA) specific tables. 1st April 2010 to 31st March 2011. Accessed 6 Sept 2012.
  135. 135.
    Brunham RC, Pourbohloul B, Mak S, White R, Rekart ML. The unexpected impact of a Chlamydia trachomatis infection control program on susceptibility to reinfection. J Infect Dis. 2005;192(10):1836–44.PubMedCrossRefGoogle Scholar
  136. 136.
    Hoover K, Tao G. Missed opportunities for chlamydia screening of young women in the United States. Obstet Gynecol. 2008;111(5):1097–102.PubMedCrossRefGoogle Scholar
  137. 137.
    Nordin JD, Solberg LI, Parker ED. Adolescent primary care visit patterns. Ann Fam Med. 2010;8(6):511–6.PubMedCrossRefGoogle Scholar
  138. 138.
    Nguyen TQ, Ford CA, Kaufman JS, Leone PA, Suchindran C, Miller WC. Infrequent chlamydial testing among young adults: financial and regional differences. Sex Transm Dis. 2008;35(8):725–30.PubMedCrossRefGoogle Scholar
  139. 139.
    Geisler WM, Chyu L, Kusunoki Y, Upchurch DM, Hook III EW. Health insurance coverage, health care-seeking behaviors, and genital chlamydial infection prevalence in sexually active young adults. Sex Transm Dis. 2006;33(6):389–96.PubMedCrossRefGoogle Scholar
  140. 140.
    Sheringham J, Sowden S, Stafford M, Simms I, Raine R. Monitoring inequalities in the National Chlamydia Screening Programme in England: added value of ACORN, a commercial geodemographic classification tool. Sex Health. 2009;6(1):57–62.PubMedCrossRefGoogle Scholar
  141. 141.
    Batteiger BE, Tu W, Ofner S, et al. Repeated Chlamydia trachomatis genital infections in adolescent women. J Infect Dis. 2010;201(1):42–51.PubMedCrossRefGoogle Scholar
  142. 142.
    Trelle S, Shang A, Nartey L, Cassell JA, Low N. Improved effectiveness of partner notification for patients with sexually transmitted infections: systematic review. BMJ. 2007;334(7589):354–7.PubMedCrossRefGoogle Scholar
  143. 143.
    Estcourt C, Sutcliffe L. Moving partner notification into the mainstream of routine sexual health care. Sex Transm Infect. 2007;83(2):169–72.PubMedCrossRefGoogle Scholar
  144. 144.
    Ostergaard L, Andersen B, Olesen F, Moller JK. Efficacy of home sampling for screening of Chlamydia trachomatis: randomised study. BMJ. 1998;317(7150):26–7.PubMedCrossRefGoogle Scholar
  145. 145.
    Macleod J, Salisbury C, Low N, et al. Coverage and uptake of systematic postal screening for genital Chlamydia trachomatis and prevalence of infection in the United Kingdom general population: cross sectional study. BMJ. 2005;330(7497):940–2.PubMedCrossRefGoogle Scholar
  146. 146.
    Scott LaMontagne D, Baster K, Emmett L, et al. Incidence and reinfection rates of genital chlamydial infection among women aged 16–24 years attending general practice, family planning and genitourinary medicine clinics in England: a prospective cohort study by the Chlamydia Recall Study Advisory Group. Sex Transm Infect. 2007;83(4):292–303.PubMedCrossRefGoogle Scholar
  147. 147.
    Maciosek MV, Coffield AB, Edwards NM, Flottemesch TJ, Goodman MJ, Solberg LI. Priorities among effective clinical preventive services: results of a systematic review and analysis. Am J Prev Med. 2006;31(1):52–61.PubMedCrossRefGoogle Scholar
  148. 148.
    Brandt AM. No magic bullet: a social history of venereal disease in the United States since 1880. 2nd ed. New York: Oxford University Press, Inc.; 1985.Google Scholar
  149. 149.
    Cowan FM, Plummer M. Biological, behavioural and psychological outcome measures. In: Stephenson JM, Imrie J, Bonell C, editors. Effective sexual health interventions. Issues in experimental evaluation. Oxford: Oxford University Press; 2003. p. 111–35.CrossRefGoogle Scholar
  150. 150.
    Nadala EC, Goh BT, Magbanua JP, et al. Performance evaluation of a new rapid urine test for chlamydia in men: prospective cohort study. BMJ. 2009;339:b2655.PubMedCrossRefGoogle Scholar
  151. 151.
    Gaydos CA, Dwyer K, Barnes M, et al. Internet-based screening for Chlamydia trachomatis to reach non-clinic populations with mailed self-administered vaginal swabs. Sex Transm Dis. 2006;33(7):451–7.PubMedCrossRefGoogle Scholar
  152. 152.
    Gottlieb SL, Martin D, Xu F, et al. Summary: the natural history and immunobiology of Chlamydia trachomatis genital infection and implications for chlamydia control. J Infect Dis. 2010;201(S2):190–204.CrossRefGoogle Scholar
  153. 153.
    Darville T, Hiltke TJ. Pathogenesis of genital tract disease due to Chlamydia trachomatis. J Infect Dis. 2010;201(S2):114–25.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  • Nicola Low
    • 1
    Email author
  • William M. Geisler
    • 2
  • Judith M. Stephenson
    • 3
  • Edward W. HookIII
    • 2
    • 4
  1. 1.Division of Clinical Epidemiology and Biostatistics, Institute of Social and Preventive MedicineUniversity of BernBernSwitzerland
  2. 2.Division of Infectious DiseasesUniversity of Alabama at BirminghamBirminghamUSA
  3. 3.Institute for Women’s HealthUniversity College LondonLondonUK
  4. 4.Jefferson County Department of HealthBirminghamUSA

Personalised recommendations